Loading...
Back to narrative

BNGO: Clinical Study Results Will Drive Increased Demand Through 2025

Digital Pathology Transition Will Advance Precision Medicine Adoption

BNGO logo
BNGO
AnalystConsensusTarget
Not Invested
Published 16 Apr 2025

Update shared on 25 Nov 2025

Fair value Decreased 21%
PreviousNext
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
-86.3%
7D
-1.2%

Analysts have lowered their price target for Bionano Genomics from $9.50 to $7.50 per share, citing updated forecasts for valuation and growth.

What's in the News

  • Bionano Genomics initiated earnings guidance for the fourth quarter of 2025, projecting revenue between $7.5 million and $7.9 million, and reiterated full-year 2025 revenue guidance of $26.0 million to $30.0 million (company guidance).
  • A new peer-reviewed study published in Cancers by The University of Texas MD Anderson Cancer Center showed that Bionano's optical genome mapping (OGM) technology can detect gene rearrangements and fusions in acute leukemia cases that were missed by targeted RNA-sequencing. This highlights the clinical value of combining OGM and RNA-seq (company announcement).
  • The company completed a follow-on equity offering and raised $10 million through common stock and warrants (company filing).
  • Multiple lock-up agreements affecting common stock, stock options, and warrants are set to expire on November 17, 2025, which may lead to changes in share availability (company disclosure).

Valuation Changes

  • The consensus analyst price target has fallen significantly, from $9.50 to $7.50 per share.
  • The discount rate has risen, increasing from 9.18% to 10.15%.
  • The revenue growth expectation has risen slightly, from 28.88% to 29.34%.
  • The net profit margin forecast has increased from 14.21% to 15.51%.
  • The future P/E ratio estimate has risen notably, from 7.41x to 12.48x.

Have other thoughts on Bionano Genomics?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.